Disease · MONDO_0021071
laryngeal neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. laryngeal neoplasm. Diseases, record MONDO_0021071. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0021071
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Cancer of Larynx, Cancer of the Larynx, Cancer, Laryngeal, Cancer, Larynx, Cancers, Laryngeal, Cancers, Larynx, LARYNGEAL NEOPL, LARYNX NEOPL, Laryngeal Cancer, Laryngeal Cancers, Laryngeal Neoplasms, Larynx Cancer, Larynx Cancers, Larynx Neoplasms, NEOPL LARYNGEAL, Neoplasm, Laryngeal, Neoplasm, Larynx, Neoplasms, Laryngeal, Neoplasms, Larynx, laryngeal tumor, laryngeal tumour, larynx neoplasm, larynx neoplasm (disease), larynx tumor, larynx tumour, neoplasm of larynx, neoplasm of the larynx, tumor of larynx, tumor of the larynx, tumour of larynx, tumour of the larynx
- Open Targets
Drugs17
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| DOCETAXEL | CHEMBL3545252 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| FLUOROURACIL | CHEMBL185 | Small molecule | Phase 3 | ClinicalTrials.gov | 6 | 6 | 6 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| PACLITAXEL | CHEMBL428647 | Small molecule | Phase 2 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| CETUXIMAB | CHEMBL1201577 | Antibody | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TORIPALIMAB | CHEMBL4297843 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| HYDROXYUREA | CHEMBL467 | Small molecule | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| NIVOLUMAB | CHEMBL2108738 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| PEMBROLIZUMAB | CHEMBL3137343 | Antibody | Phase 2 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 17
See all 17 drugsTargets29
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 10 of 29
See all 29 targetsTrials19
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04030455 | Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer | Phase 2 | 28 | 2026-02-17 | Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8 | CISPLATIN, DOCETAXEL, PEMBROLIZUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT03894891 | Induction TPN Followed by Nivolumab With Radiation in Locoregionally Advanced Laryngeal and Hypopharyngeal Cancer | Phase 2 | 6 | 2023-12-20 | Head and Neck Cancer | CISPLATIN, DOCETAXEL, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT00599131 | Cetuximab and Radiation Therapy in Laryngeal Cancer Patients Who Have Responded to One Cycle of Chemotherapy (SPORE) | Phase 2 | 4 | 2014-06-16 | Cancer of Larynx | CETUXIMAB, CISPLATIN, DOCETAXEL, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov |
| NCT00002839 | Combination Chemotherapy Plus Radiation Therapy To Preserve the Larynx in Patients With Cancer of the Hypopharynx or Larynx | Phase 3 | 564 | Head and Neck Cancer | CISPLATIN, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT03340896 | Trial of Laryngeal Preservation Comparing Induced CT Followed by RT vs CT Concomitant to RT | Phase 3 | 256 | Head and Neck Squamous Cell Carcinoma | CISPLATIN, DOCETAXEL, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00534729 | Organ Preservation: Weekly Carboplatin & Taxol w/Concurrent RT for Locally Advanced Laryngeal & Hypopharyngeal CA | Not applicable | 200 | Laryngeal Neoplasms, Hypopharyngeal Neoplasms | CARBOPLATIN, PACLITAXEL | Its record names the disease | ClinicalTrials.gov | |
| NCT00508664 | Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) | Phase 2 | 180 | Squamous Cell Carcinoma of the Hypopharynx, Larynx Carcinoma | CETUXIMAB, CISPLATIN, DOCETAXEL, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov | |
| NCT00169247 | Radiotherapy With Cisplatin Versus Radiotherapy With Cetuximab After Induction Chemotherapy for Larynx Preservation | Phase 2 | 156 | Larynx Cancer, Hypopharynx Cancer | CETUXIMAB, CISPLATIN | Its record names the disease | ClinicalTrials.gov | |
| NCT06000137 | The Comparison of the Analgesic Effects of Dezocine and Sufentanil in Patient-controlled Analgesia After Laryngectomy | Not applicable | 129 | Patient-controlled Analgesia | DEZOCINE, SUFENTANIL | Its record names the disease | ClinicalTrials.gov | |
| NCT01073683 | Induction Docetaxel/Cisplatin/5-fluorouracil (TPF) as Selector for Chemo Radiation Therapy (RT) Versus Partial Laryngectomy in Advanced Laryngeal Cancer | Phase 2 | 100 | Larynx Cancer | CISPLATIN, DOCETAXEL, FLUOROURACIL | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials0
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
None in this release.
Papers from its trials5
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0021071
GET https://conductscience.org/api/diseases/v1/MONDO_0021071/targets?page=2